The risk of developing allopurinol-induced severe cutaneous adverse drug reactions is 1.6%–2.0% for HLA-B*58:01 carriers, for patients with chronic renal insufficiency the risk is increased to 8%–18% to develop a SCAR (Jung et al., 2014; Park et al., 2019). This evidence concerns the gene HLA-B and chronic kidney disease.